The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Phase II study of camidanlumab tesirine in R/R Hodgkin lymphoma
Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, discusses the rationale, design, and results of a Phase II study investigating the clinical efficacy and tolerability of the antibody-drug conjugate (ADC) camidanlumab tesirine in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) who have been treated with brentuximab vedotin and PD-1 inhibitors (NCT04052997). The study reported a promising activity with a long-lasting response, and showed that camidanlumab tesirine did not have an impact on subsequent transplant efficacy. In addition, patients experienced primarily hematological toxicities as well as Guillain-Barré syndrome (GBS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
